343 related articles for article (PubMed ID: 17926654)
1. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD; Valette G; Darque A; Zhou XJ; Sommadossi JP
J Am Soc Mass Spectrom; 2000 Dec; 11(12):1134-43. PubMed ID: 11118121
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
Rodriguez JF; Rodriguez JL; Santana J; García H; Rosario O
Antimicrob Agents Chemother; 2000 Nov; 44(11):3097-100. PubMed ID: 11036029
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
Anderson PL; Zheng JH; King T; Bushman LR; Predhomme J; Meditz A; Gerber J; Fletcher CV
AIDS; 2007 Sep; 21(14):1849-54. PubMed ID: 17721092
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.
Dumond JB; Yang KH; Kendrick R; Reddy YS; Kashuba AD; Troiani L; Bridges AS; Fiscus SA; Forrest A; Cohen MS
Antimicrob Agents Chemother; 2015 Oct; 59(10):6395-401. PubMed ID: 26239974
[TBL] [Abstract][Full Text] [Related]
7. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
8. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Rodriguez-Torres M; Torriani FJ; Soriano V; Borucki MJ; Lissen E; Sulkowski M; Dieterich D; Wang K; Gries JM; Hoggard PG; Back D
Antimicrob Agents Chemother; 2005 Oct; 49(10):3997-4008. PubMed ID: 16189072
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
Fletcher CV; Kawle SP; Kakuda TN; Anderson PL; Weller D; Bushman LR; Brundage RC; Remmel RP
AIDS; 2000 Sep; 14(14):2137-44. PubMed ID: 11061655
[TBL] [Abstract][Full Text] [Related]
10. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
11. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers.
Durand-Gasselin L; Pruvost A; Dehée A; Vaudre G; Tabone MD; Grassi J; Leverger G; Garbarg-Chenon A; Bénech H; Dollfus C
Antimicrob Agents Chemother; 2008 Jul; 52(7):2555-63. PubMed ID: 18426897
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
[TBL] [Abstract][Full Text] [Related]
13. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Rower JE; Meditz A; Gardner EM; Lichtenstein K; Predhomme J; Bushman LR; Klein B; Zheng JH; Mawhinney S; Anderson PL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3011-9. PubMed ID: 22391541
[TBL] [Abstract][Full Text] [Related]
14. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C
J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
16. Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.
Hurwitz SJ; Asif G; Schinazi RF
Antivir Chem Chemother; 2007; 18(6):329-41. PubMed ID: 18320937
[TBL] [Abstract][Full Text] [Related]
17. Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.
Font E; Rosario O; Santana J; García H; Sommadossi JP; Rodriguez JF
Antimicrob Agents Chemother; 1999 Dec; 43(12):2964-8. PubMed ID: 10582890
[TBL] [Abstract][Full Text] [Related]
18. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
19. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
Anderson PL; Kakuda TN; Kawle S; Fletcher CV
AIDS; 2003 Oct; 17(15):2159-68. PubMed ID: 14523272
[TBL] [Abstract][Full Text] [Related]
20. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
